CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil.
The adenosine A2 receptor antagonist CGS 15943 (0.1 mg/kg, i.p.) was tested for cerebroprotective activity in a gerbil stroke model. CGS 15943 markedly reduced stroke injury assessed by locomotor activity monitoring and by histopathological measurement of hippocampal CA1 pyramidal cell injury. It is proposed that a previously demonstrated reduction in the ischemia/reperfusion-evoked release of excitotoxic amino acids following CGS 15943 administration could account for its cerebroprotective actions.
Gao
Y
Y
Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201.
Phillis
J W
JW
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D005849:Gerbillinae; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D058915:Purinergic P1 Receptor Antagonists; D017966:Pyramidal Cells / Q000187:drug effects / Q000473:pathology; D011799:Quinazolines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines; D014230:Triazoles; C052410:9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine